Articles tagged "Kidney transplantation"

2018 American Transplant Congress
Predicting Survival after Deceased-Donor Kidney Transplants by Donor-Recipient Match: Who Can Tolerate a High-KDPI Kidney?
S. Bae, J. Garonzik Wang, K. Jackson, A. Thomas, X. Luo, A. Massie, D. Segev.
Johns Hopkins School of Medicine, Baltimore, MD.
Deceased-donor kidney transplantation (DDKT) with high-KDPI kidneys carries an additional risk of mortality and graft failure, which could be tolerable for some candidates but detrimental…
2018 American Transplant Congress
The Impact of Rituximab Dose on Hepatitis B Virus Reactivation in HBsAg-Negative/anti-HBc-Positive Kidney Transplant Recipients
J. Lee,¹ J. Park,² Y. Jung,¹ D. Kim,¹ J. Lee,¹ S. Song,³ J. Lee,⁴ J. Lee,¹ B. Kim,⁵ M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹
¹Surgery, Yonsei University College of Medicine, Seoul, Korea; ²Internal Medicine (Gastroenterology), Yonsei University College of Medicine, Seoul, Korea; ³Surgery, Ewha Womans University, School of Medicine, Seoul, Korea; ⁴Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea; ⁵Internal Medicine (Nephrology), Yonsei University College of Medicine, Seoul, Korea.
Background: Hepatitis B virus (HBV) reactivation is well-recognized complication of rituximab. Although use of rituximab for sensitized patients continues to increase in kidney transplantation, the…
2018 American Transplant Congress
Redo Kidney Transplant in FSGS
J. Verbesey, A. Javaid, S. Yi, G. Vranic, A. Gilbert, P. Abrams, S. Ghasemian, J. Moore, B. Thomas, M. Cooper, B. Javaid.
Kidney and Pancreas Transplant Program, MedStar Georgetown Transplant Institute, Washington, DC.
Objective: Analyze risk of graft failure due to recurrent FSGS in patients with prior failed kidney transplants under consideration for a subsequent transplant.Results: We identified…
2018 American Transplant Congress
Prevalence of Frailty among Kidney Transplant Recipients in the United States
A. Thomas,¹ A. Shaffer,¹ H. Ying,¹ S. Norman,² D. Segev,¹ M. McAdams-DeMarco.¹
¹JHU, Baltimore; ²University of Michigan, Ann Arbor.
Frailty, a measure of physiologic reserve, increases the risk of delayed graft function, longer length of stay, early hospital readmission, immunosuppression intolerance, and mortality among…
2018 American Transplant Congress
Anti-TIRC7 Antibody Acts Synergistically with Tacrolimus in Promoting Graft Survival in a Rat Kidney Transplant Model
S. Tullius,¹ Y. Kumamoto,² U. Nalan.³
¹Department of Medicine, Brigham and Women's Hospital, Boston, MA; ²Department of Surgery, Kitasato University School of Medicine, Kanagawa, Sagamihara, Japan; ³Institute for Medical Immunology, University Hospital Charite, Berlin, Germany.
Background: Induction of T cell immune response c-DNA (TIRC7) is restricted to activated lymphocytes. Modulation of TIRC7 signalling prevents immune activation specifically at the site…
2018 American Transplant Congress
Extended Experience Using Tocilizumab (Anti-IL6R, TCZ) for the Treatment of Chronic Antibody Mediated Rejection (CABMR)
J. Choi,¹ O. Aubert,² S. Louie,¹ N. Ammerman,¹ A. Vo,¹ A. Peng,¹ E. Huang,¹ R. Najjar,¹ D. Puliyanda,¹ S. Sethi,¹ M. Haas,¹ K. Lim,¹ A. Loupy,² S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Paris Translational Center for Organ Transplantation, Paris, France.
Introduction: Disruption of the IL-6/IL-6R pathways may have benefits in treating allograft rejection. We reported our experience with anti-IL-6R (TCZ) as a treatment for CABMR…
2018 American Transplant Congress
Modifiable Causes of Racial Disparities in Living Donor Kidney Transplant
J. Beaumont,¹ J. Peipert,^1,2 C. Anderson,² A. Paiva,³ M. Robbins,³ A. Waterman.^1,2
¹Terasaki Research Institute, Los Angeles, CA; ²Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, CA; ³Department of Psychology, University of Rhode Island, Kingston, RI.
Racial disparities between White and non-White patients in receiving living donor kidney transplants (LDKT) are large and widespread. Yet, the causes of this disparity are…
2018 American Transplant Congress
Evaluating the Impact of Pre-Transplant Malignancy on Outcomes after Kidney Transplantation: A National Database Analysis over a Twenty-Two Year Period
D. Livingston-Rosanoff, L. Wilke, G. Leverson, D. Foley.
Dept. of Surgery, University of Wisconsin, Madison, WI.
Introduction: Patients with a history of malignancy prior to kidney transplantation are known to develop more post-transplant malignancies and have inferior outcomes. However, there have…
2018 American Transplant Congress
Effect of Acute Vascular Inflammation (v) on Death Censored Graft Failure (DCGF) Following Kidney Transplant (KTx)
J. Grande,¹ L. Hunsicker,² R. LeDuc,³ A. Matas, The DeKAF Consortium.
¹Pathology, Mayo Clinic, Rochester, MN; ²Int. Med., U Iowa, Iowa City, IA; ³Biostatistics and Surgery, U Minnesota, Minneapolis, MN.
The impact of acute vascular inflammation in acute cellular or humoral rejection following KTx, and the effect of isolated vascular inflammatory lesions on late DCGF,…
2018 American Transplant Congress
Antihypertensive Medication Use after Kidney Transplant: Practice Variation and Clinical Outcomes
H. Yamout,^1,2 R. Ouseph,¹ M. Schnitzler,¹ H. Xiao,¹ V. Dharnidharka,³ A. Naik,⁴ N. Lam,⁵ F. Koraishy,^1,2 H. Randall,¹ D. Brennan,⁶ D. Segev,⁶ B. Kasiske,⁷ G. Hess,⁸ K. Lentine.¹
¹Saint Louis Univ, St. Louis; ²St. Louis VA, St. Louis; ³Washington Univ, St. Louis; ⁴Univ Michigan, Ann Arbor, Canada; ⁵Univ Alberta, Edmonton; ⁶Johns Hopkins, Baltimore; ⁷Hennepin County, Minneapolis; ⁸Symphony Health, Conshohocken.
Hypertension is common among kidney transplant (KTx) recipients, but the impact of antihypertensive medication (AHM) choice on patient and graft outcomes is not well defined.We…